Calendar

Cloudflare's Q3 revenue outlook of $736–737M was above the cited $733.3M consensus, and Q2 revenue and large-customer metrics showed strong growth. However, the company-guided $0.34 non-GAAP EPS was below the cited $0.35 consensus, its latest available pre-event tape showed a sharp Oct. 30 selloff, and the technology/software tape was weak on Nov. 2. The positive revenue gap does not offset failed EPS and tape requirements.

Airbnb has a plausible operating-growth narrative and a strong Nov. 2 rebound that closed near the session high, while consensus implies year-over-year EPS and revenue growth. But no checked source established positive recent EPS revisions/ESP or revenue-estimate upside, and the available volume data do not show the required 1.5x accumulation; this does not qualify as a pre-event surprise setup.

Zacks reported that EOG's Q3 EPS consensus had risen 17.04% over 30 days, a positive estimate signal, but revenue upside was not established and the stock fell sharply on Nov. 2 on weak closing location. Critically, EOG's own Sept. 22 release schedules its Q3 results call for Nov. 6, conflicting with the supplied Nov. 5 date; this assessment is disqualified pending reliable date resolution.

A search result explicitly says Lumentum reported revenue on Nov. 2, before this screen’s Nov. 3 anchor, while the supplied calendar lists a Nov. 5 event; with event status/date in conflict and an extreme Nov. 2 price decline on elevated volume, this cannot qualify as a pre-event setup.

SPG has a confirmed Nov. 5 report, a small upward EPS revision, and firm recent trading, but a credible revenue-consensus/upside source and an abnormal-volume signal were not established; it does not meet the required earnings-surprise evidence threshold.

The consensus sources support substantial expected revenue growth and the prior quarter showed strong revenue, but the checked EPS consensus is inconsistent across providers and there is no verified positive EPS revision/ESP signal. NTRA fell 8.54% on November 2 and closed near the session low; that price action fails the required pre-event strength and close-location checks despite elevated volume and an otherwise active growth story.

Zacks reported a positive 30-day EPS consensus revision and a Most Accurate Estimate above consensus, but revenue estimates vary materially between sources. That positive estimate signal is outweighed by a sharp Nov. 2 selloff: shares fell 6.75% on elevated volume, and the Nov. 2 close was near the day’s low. An Oct. 30 strong close location does not offset the weak latest tape; recent XLE data was insufficient to establish sector health.

TEAM has a scheduled report and prior cloud/AI product momentum, but the checked pre-event evidence did not establish a positive current revenue revision or upside indicator; the latest located close was weak and near the session low, so the required price/volume confirmation is absent.

Con Edison has continuing infrastructure investment and its first-half 2026 earnings improved year over year, but the pre-event Zacks preview cautioned that estimates made a beat difficult to call conclusively. The available late-October tape showed modest strength and no verified high-close/accumulation pattern; this is a defensive utility setup, not a supported surprise signal.

Microchip’s August guidance for Q2 FY27 was materially above the then-cited consensus and the recovery has produced recent beats, but the current street forecast is broadly in line with that guide; the verified Nov. 2 close was weak and near the session low, so the required pre-earnings tape confirmation is absent.

Live Nation has supportive year-over-year business indicators, including higher deferred revenue and Q2 revenue growth, and a modestly positive three-month revenue estimate trend. However, Q3 EPS estimates were cut sharply, the recent tape did not verify required strength or accumulation, and a states’ antitrust jury verdict remains a material legal overhang.

Arm's investor-relations results page announced a Q2 FY2027 results webcast for Nov 4, creating a date discrepancy with the supplied Nov 5 earnings date. A reliable pre-event consensus EPS and revenue pair or revision/whisper data was not established, and the stock had declined sharply with high volume into Nov 2. Do not qualify this setup.

Moderna's stock had substantial recent price strength and a prior business catalyst, but the checked Zacks preview described expected year-over-year declines in earnings and revenue, and its annual loss estimate had widened over the prior month. No positive upcoming-quarter EPS revision or revenue upside indicator was verified, so the required estimate signals are absent despite the favorable tape.

BAM has a published Q3 EPS and revenue consensus and its IR calendar lists a Nov. 6 results event, but estimates are not accompanied by evidence of positive revisions or revenue upside. Available daily price history was stale/inconsistent around the as-of date, preventing a reliable pre-event tape and volume assessment.

Humana's investor-relations calendar confirms the November 6 call, and third-party estimates show about a $1.03 quarterly loss on $40.46B revenue. EPS consensus was revised down 2.23% over 30 days, while the stock weakened into the event and recent sessions lacked the required close-location and volume confirmation; Medicare cost and policy risks further limit an upside-surprise case.

Although a source provided pre-event EPS and revenue consensus figures and the company has material power-market exposure, the checked evidence showed the upcoming date as an estimate rather than confirmed by the secondary source, no positive revisions or upside indicators, and a recent pullback from the October 23 close; this is not a qualifying surprise setup.

Monster's Oct. 29 and Nov. 2 pre-event research indicated a negative EPS revision/ESP signal, despite forecast year-over-year sales growth and recent positive price movement. More importantly, the company's investor-relations release announced results for Nov. 5, conflicting with the supplied Nov. 6 date; the earnings date therefore cannot be treated as confirmed for this assessment.